Crystal structure of the T315I mutant of AbI kinase.

@article{Zhou2007CrystalSO,
  title={Crystal structure of the T315I mutant of AbI kinase.},
  author={Tianjun Zhou and Lois E Parillon and Feng Li and Yihan Wang and Jeff Keats and Sarah D K Lamore and Qihong Xu and William Shakespeare and David C Dalgarno and Xiaotian Zhu},
  journal={Chemical biology & drug design},
  year={2007},
  volume={70 3},
  pages={171-81}
}
Imatinib (Gleevec) is currently the frontline therapy for chronic myeloid leukemia (CML), a disease characterized by the presence of a constitutively activated chimeric tyrosine kinase protein Bcr-AbI. However, drug resistance often occurs at later stages of the disease, principally because of the occurrence of mutations in the kinase domain. Second generation Bcr-AbI inhibitors, such as dasatinib and nilotinib are capable of inhibiting many imatinib-resistant forms of the kinase but not the… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
23 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

Similar Papers

Loading similar papers…